Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?

Author： Jordheim Lars Petter   Dumontet Charles  

Publisher： Future Medicine

ISSN： 1752-0363

Source： Biomarkers in Medicine, Vol.7, Iss.4, 2013-08, pp. : 663-671

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Randomized clinical trial of adjuvant chemotherapy with S‐1 versus gemcitabine after pancreatic cancer resection

By  

BRITISH JOURNAL OF SURGERY, Vol. 102, Iss. 7, 2015-06 ,pp. : 746-754

John Wiley & Sons Inc

Access to resources Recommend Favorite

Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine

By  

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, Vol. 19, Iss. 6, 2012-11 ,pp. : 717-722

John Wiley & Sons Inc

Access to resources Recommend Favorite

Erratum to: Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine

By  

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, Vol. 19, Iss. 6, 2012-11 ,pp. : 723-723

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Prognostic Model to Predict Clinical Outcomes with First-Line Gemcitabine-Based Chemotherapy in Advanced Pancreatic Cancer

By  

Oncology, Vol. 80, Iss. 3-4, 2011-06 ,pp. : 175-180

Karger

Access to resources Recommend Favorite

Clinical Benefit Response in Pancreatic Cancer Trials Revisited

By  

Oncology Research and Treatment, Vol. 37, Iss. 1-2, 2014-01 ,pp. : 42-48

Karger

Access to resources Recommend Favorite